Novo Nordisk's $1.3 Billion Deal Targets a Big Obesity-Drug Problem
Novo Nordisk (NVO, Financials), has agreed to pay up to 1.165 billion ($1.3 billion) for access to drug-delivery technology that could help the company develop obesity and diabetes treatments requiring fewer injections.The Danish drugmaker signed a global licensing and collaboration agreement with…